The porphyria therapies market is projected to grow at an annualized rate of 10.97%

Several novel and innovative therapeutic approaches, both small molecule and biologics, are being currently investigated at various phases of development in order to avoid the beginning of disease-induced attacks and other long-term effects of porphyria

Roots Analysis has announced the addition of “Porphyria Targeting Therapies Market, 2021-2030” report to its list of offerings.

Porphyria is a rare disorder that is characterized by excessive accumulation of porphyrin, a compound that aids in the formation of heme (an essential part of hemoglobin that helps carry oxygen in blood). Any anomaly caused by genetic or acquired abnormalities in heme biosynthesis (produced majorly in bone marrow and liver) can result in toxicity. It is worth highlighting that, till date, more than 1,000 mutations that can cause porphyria have been identified. However, prevalence of porphyria still remains unknown. Several treatment options such as gene therapy, proteasome inhibition and pharmacologic chaperones are currently being investigated among various other targeted treatment options.

To order this 130+ slides report, which features 90+ figures, please visit https://www.rootsanalysis.com/reports/porphyria-pipline-review.html

Leave a Reply

Your email address will not be published. Required fields are marked *